{"id":11355,"date":"2021-10-26T14:52:37","date_gmt":"2021-10-26T12:52:37","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=11355"},"modified":"2022-03-25T12:39:29","modified_gmt":"2022-03-25T11:39:29","slug":"article-in-the-current-issue-of-pharma-recht-specialist-journal-for-pharmaceutical-law","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/jp\/publications\/article-in-the-current-issue-of-pharma-recht-specialist-journal-for-pharmaceutical-law\/","title":{"rendered":"Admissibility of non-challenge clauses and pay-for-delay agreements in settlements and license, 2021"},"content":{"rendered":"\n<p>by <a href=\"https:\/\/www.maiwald.eu\/jp\/team\/marco-stief\/\">Dr Marco Stief<\/a><\/p>\n\n\n\n<p>In the current October issue of Pharma Recht \u2013 a specialist journal for pharmaceutical law our partner Dr. Marco Stief has written an article with the equally complex and practically relevant topic \u201cAdmissibility of non-challenge clauses and pay-for-delay agreements in settlements and license agreements\u201d.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11355","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/11355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":5,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/11355\/revisions"}],"predecessor-version":[{"id":16552,"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/publikationen\/11355\/revisions\/16552"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/jp\/wp-json\/wp\/v2\/media?parent=11355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}